How generic drug suppliers’ litigation histories expose supply chain risk, financial fragility, and competitive staying power — before you sign […]

A practical playbook for formulation vendors, CDMOs, and excipient suppliers on how to mine patent loss-of-exclusivity data to find, time,

The $200 Billion Window Nobody in Sales Talks About Between 2025 and 2030, an estimated $200 billion in annual branded

How rare disease drugmakers build market protection that no generic can touch — and what every analyst needs to know

The Patent Cliff Is Not an Event. It’s a Calendar. Every biologic drug that ever earned blockbuster status is on

Across hundreds of DrugChatter queries, a clear pattern emerges: patients and caregivers are not just asking about drugs—they’re asking what

The Evergreening Problem, Defined Precisely Evergreening is not a conspiracy. It is a rational economic strategy executed by legal means,

The blockbuster drug model has a built-in expiration date. From the moment a pharmaceutical company files its first patent, the

Part One: What GPT-Rosalind Is and What OpenAI Is Selling The Model Architecture GPT-Rosalind is the first in what OpenAI